TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FBF1 Full-Length, F-Box Domain, and Fas-1 Domain Mutant Recombinant Proteins. High purity (>95%), Endotoxin <1EU/ug, Sequence Verified, HEK293 Expressed, Theoretical MW confirmed. | View FBF1 Products |
| Gene Delivery | FBF1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. Sequence Verified. Optional C-terminal mCherry tag for live imaging. | View FBF1 Products |
| Benchmark Ab | Anti-FBF1 Recombinant Antibody. Recombinant positive control for IHC/WB/co-IP and localization studies. Sequence-defined. | View FBF1 Products |
| Validator | FBF1 siRNA Set. Validated sets for knockdown verification and orthogonal specificity checks. >85% knockdown efficiency. | View FBF1 Products |
| Related Target | FAS – Primary biological partner for Fas-mediated apoptosis regulation. | View FAS Products |
| Related Target | CEP164 – Synergistic ciliary appendage target for ciliopathy pathway mapping. | View CEP164 Products |
| Related Target | CEP63 – Core centriole duplication factor; upstream regulator of FBF1 centriolar recruitment. | View CEP63 Products |
| Related Target | PLK4 – Master kinase controlling centriole biogenesis; synthetic lethal node. | View PLK4 Products |
| Related Target | CPAP (CENPJ) – Centriole length control; functional partner in centrosome amplification. | View CENPJ Products |
| Related Target | SKP1 – SCF Complex Adaptor (Direct Binding Partner). | View SKP1 Products |
| Related Target | CUL1 – SCF E3 Ligase Scaffold. | View CUL1 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) Screening (including FBF1-SKP1, FBF1-FAS) | Domain-defined recombinant proteins (Full-length, F-box, Fas-1 domain mutants) with >95% purity, Endotoxin <1EU/ug, sequence verified, optimal for SPR/BLI/FP assays. |
| Intracellular Target Accessibility & Centriolar Localization | Lentivirus-mediated stable expression (with optional mCherry tag) preserves native processing and enables live imaging of centriolar recruitment. |
| Lack of Reliable Controls / Selectivity | Sequence-verified benchmark antibodies (recombinant mAb for co-IP/WB) and orthogonal specificity panels (F-box family counter-screening). |
| False Positives in Knockdown | Validated siRNA sets with >85% knockdown efficiency for phenotype rescue and specificity checks. |
| SCF Complex Assembly & Functional Studies | Co-expression of FBF1 + SKP1 available; full-length and domain constructs for AlphaScreen/TR-FRET complex assembly assays. |
Live FBF1 R&D Tracker
- ➤ View Active Clinical Trials
- ➤ Latest Apoptosis & Ciliopathy Research
- ➤ Latest Centrosome & Centriole Biology Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
FBF1 (Fas-binding factor 1) drug discovery is concentrated in early-stage research across multiple therapeutic areas: ciliopathies (e.g., nephronophthisis), oncology (centrosome amplification and apoptosis evasion), male contraception, and autoimmune disease. The target exerts dual functions via Fas-mediated apoptosis regulation and ciliogenesis, and is also a key component of the SCF E3 ubiquitin ligase complex through its F-box domain. The global pipeline remains preclinical, with major academic and biotech players exploring PPI inhibitors (e.g., disrupting FBF1-SKP1), targeted protein degradation (PROTACs), and genetic therapies (siRNA, gene replacement). Common missense variants (rs1135889, rs2305913, rs7218738) associated with ciliopathy phenotypes underscore the need for careful genotype-phenotype correlation in preclinical models. Future outlook includes expansion into rare diseases (orphan drug benefits) and synthetic lethality strategies combining FBF1 modulation with PLK4 or CHK1 inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / siRNA | Academic / Early Biotech | Ciliopathies (Nephronophthisis) | Knockdown/Rescue Assays (need sequence-verified lentivirus) |
| Small Molecule PPI Inhibitor | Academic Labs, Emerging Biotech | Male Contraception, Cancer, Autoimmune | SPR/FP assays (need pure F-box or Fas-1 domain proteins) |
| Targeted Protein Degradation (PROTAC) | Preclinical Innovators | Oncology (centrosome amplification) | Target engagement (CETSA), cell viability assays |
| Biomarker Diagnostics | Translational Labs | Solid Tumors | Antibody specificity (benchmark recombinant antibodies) |
| Biochemical Probe / Structural Biology | Consortia | Target Validation | Crystallography-grade full-length/domain proteins |
Known Genetic Variants of FBF1
- rs1135889 (UniProt Q8TES7 VAR_034659)
- rs2305913 (UniProt Q8TES7 VAR_034660)
- rs7218738 (UniProt Q8TES7 VAR_034661)
These variants may affect protein function and should be considered when designing assays or selecting model systems. Evidence derived from UniProt.
Molecular Differentiation & Assay Strategy (R&D Recommendations)
- Affinity & Binding Kinetics: Use high-sensitivity SPR/ITC for weak PPIs (Kd ~μM). TarMart provides high-purity domain proteins optimized for these platforms.
- Conformational Integrity: WD40 domain integrity is critical for centriolar localization; comparative studies using full-length vs. domain constructs are recommended.
- Complex Specificity: Cross-screen against F-box family members (FBXL, FBXW, FBXO) using TarMart’s homolog protein panels to achieve selective inhibition.
- Recommended Assays: AlphaScreen/TR-FRET for FBF1-SKP1 interaction; centriole counting by immunofluorescence (γ-tubulin/centrin) in hTERT-RPE1 cells; ciliogenesis rescue assays under serum starvation. TarMart supplies validated reagents including lentivirus with mCherry tag, siRNA sets, and co-expression systems for SCF complex assembly studies.